// App-Quantinova.ai

Sa1864 : Aspirin Downregulates Cell Survival and mTOR Effector Ps6k in Barret-s Esophagus Patients: Data From a Randomized, Double-Blind, Phase II Chemoprevention Trial

Researchers

Presenter

  • Gary W. Falk

Principal Investigators

  • Yvonne Romero

  • Norman E. Marcon

  • Thomas G. Schnell

  • Douglas A. Corley

  • Prateek Sharma

  • Marcia R. Cruz-Correa

  • Chin Hur

  • David E. Fleischer

  • Amitabh Chak

  • Kenneth R. DeVault

  • Nathan R. Foster

  • David S. Weinberg

  • Gary DellaZanna

  • Ellen Richmond

  • Asad Umar

  • Thomas C. Smyrk

  • Sumithra Mandrekar

  • Paul J. Limburg

  • Sonia Chowdhury

  • Anushka Baruah

  • Sarah Kossak

  • Raghav Chandra

  • Ishtpreet Singh

  • Prasad G. Iyer

  • Katie Allen Ziegler

Medical Centers

  • Mayo Clinic, Jacksonville, FL

  • Division of Cancer Prevention, National Cancer Institute, Bethesda, MD.

  • University Hospitals Case Medical Center, Cleveland, OH

  • University of Pennsylvania, Philadelphia, PA

  • St. Michael's Hosp, Toronto, ON, Canada

  • Hines Veteran, Hines, IL

  • Kaiser Permanente Northern California, Oakland, CA

  • Fox Chase Cancer Center, Philadelphia, PA

  • Massachusetts General Hospital, Boston, MA

  • Mayo Clinic, Scottsdale, AZ

  • Mayo Clinic and Foundation, Rochester, MN

  • Kansas City Care Ctr, Kansas City, MO

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Esophageal Cancer

  • High grade dysplasia

  • Solid malignancies

Biomarkers

  • Caspase 3

  • Proliferation marker protein Ki-67

  • Serine/threonine-protein kinase mTOR

Drug/Treatment

  • Esomeprazole

  • Aspirin

  • Albyl-E

Outcome

  • N/A

Study Design

  • observational

  • randomized

  • double blind/blinded

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved